Hudson Bay Capital Management’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Hudson Bay Capital Management’s Portfolio NRSNW Stock Details NRSNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-86,753	Closed	-$36.4K	–	887
2024 Q1	$36.4K	Hold	86,753	–	–	﹤0.01%	621
2023 Q4	$8.68K	Hold	86,753	–	–	﹤0.01%	625
2023 Q3	$13.9K	Sell	86,753 -981	-1%	-$179	﹤0.01%	693
2023 Q2	$20.7K	Sell	87,734 -62,266	-42%	-$19.6K	﹤0.01%	721
2023 Q1	$45K	Hold	150,000	–	–	﹤0.01%	686
2022 Q4	$30K	Hold	150,000	–	–	﹤0.01%	796
2022 Q3	$32K	Hold	150,000	–	–	﹤0.01%	1016
2022 Q2	$81K	Hold	150,000	–	–	﹤0.01%	1042
2022 Q1	$90K	Hold	150,000	–	–	﹤0.01%	954
2021 Q4	$137K	Buy	+150,000	New	+$134K	﹤0.01%	934

Other funds holding NRSNW

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hudson Bay Capital Management's NRSNW Position: Q2 2024 in Review

Hudson Bay Capital Management sold out of NeuroSense Therapeutics Warrant (NRSNW) in Q2 2024, closing a stake of 86,753 shares — an estimated $36.4K sold.

Hudson Bay Capital Management first reported a position in NRSNW in Q4 2021 and held it in 10 quarters. The position peaked at $137K in Q4 2021. 4 funds tracked by Wall St. Rank hold NRSNW as of Q2 2024.

Hudson Bay Capital Management reported no remaining NeuroSense Therapeutics Warrant position as of Q2 2024 after selling out during the quarter.
Hudson Bay Capital Management sold 86,753 NeuroSense Therapeutics Warrant shares in Q2 2024, an estimated $36.4K.
Hudson Bay Capital Management first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and held it in 10 quarters.
Hudson Bay Capital Management's NeuroSense Therapeutics Warrant position peaked at $137K in Q4 2021.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q2 2024.

Based on Hudson Bay Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.